Infliximab safety profile and long-term applicability in inflammatory bowel disease: 9-year experience in clinical practice

Alimentary Pharmacology and Therapeutics

Volumn 31, Issue 5, 2010, Pages 553-560

  Zabana, Y ^a   Domenech E ^b   Manosa M ^a   Garcia Planella, E ^a   Bernal, I ^a   Cabre E ^a   Gassull, M A ^a  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

^b HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

6 MERCAPTOPURINE DERIVATIVE; ADALIMUMAB; ANTIHISTAMINIC AGENT; AZATHIOPRINE; BUDESONIDE; HYDROCORTISONE; IMMUNOGLOBULIN; INFLIXIMAB; METHOTREXATE; PREDNISONE;

ABDOMINAL ABSCESS; ACUTE LOBAL NEPHRITIS; ADOLESCENT; ADULT; AGED; AORTITIS; ARTHRITIS; ARTICLE; AUTOIMMUNE AORTITIS; BACTEREMIA; BURKITT LYMPHOMA; CLINICAL PRACTICE; COLITIS; CROHN DISEASE; DELAYED HYPERSENSITIVITY; DRUG SAFETY; ENTERITIS; ENTEROBACTERIACEAE INFECTION; ENTEROCOCCAL INFECTION; ERYTHEMA; FEMALE; GENITAL HERPES; HEMIPARESIS; HERPES LABIALIS; HERPES ZOSTER; HERPETIC MENINGITIS; HUMAN; INJECTION SITE REACTION; INVERTED PSORIASIS; LONG TERM CARE; LUPUS LIKE SYNDROME; MAJOR CLINICAL STUDY; MALE; MENINGITIS; MONONUCLEOSIS; MORTALITY; MOTOR NEUROPATHY; NEPHRITIS; NEUROLOGIC DISEASE; PHOTOSENSITIVITY; PNEUMONIA; PREMEDICATION; PRIORITY JOURNAL; PSORIASIS; PYELONEPHRITIS; SALMONELLOSIS; SEMINOMA; SERUM SICKNESS; SINUSITIS; TREATMENT OUTCOME; ULCERATIVE COLITIS;

ADOLESCENT; ADULT; AGED; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; DRUG ADMINISTRATION SCHEDULE; DRUG ERUPTIONS; DRUG EVALUATION; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; GASTROINTESTINAL AGENTS; HUMANS; HYDROCORTISONE; INFECTION; INFLAMMATORY BOWEL DISEASES; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; NEOPLASMS; PRACTICE GUIDELINES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SERUM SICKNESS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 75749141691     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2009.04206.x     Document Type: Article

References (35)

1. Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997 337 : 1029 1035.
2. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002 359 : 1541 1549.
3. Rutgeerts P, Feagan BG, Lichtenstein GR, et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology 2004 126 : 402 413. (Pubitemid 38182297)
4. Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999 340 : 1398 1405. (Pubitemid 29205403)
5. Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 2004 350 : 876 885.
6. Rutgeerts P, Sanborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005 353 : 2462 2476. (Pubitemid 41770166)
7. Carmona L, Gómez-Reino J, Rodríguez-Valverde V, et al. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum 2005 52 : 1766 1772.
8. Zabana Y, Domènech E, San Román AL, et al. Tuberculous chemoprophylaxis requirements and safety in inflammatory bowel disease patients prior to anti-TNF therapy. Inflamm Bowel Dis 2008 14 : 1387 1391.
9. Esteve M, Saro C, González-Huix F, Suarez F, Forné M, Viver JM. Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: need for primary prophylaxis. Gut 2004 53 : 1363 1365.
10. Nirmal K, Thomas M. Pneumocystis jiroveci (carinii) pneumonia after Infliximab therapy: a review of 84 cases. Dig Dis Sci 2007 52 : 1481 1484.
11. Vermeire S, Noman M, van Assche G, Baert F, D'Hanes G, Rutgeerts P. Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease. Gut 2007 56 : 1226 1231.
12. Farrell RJ, Alsahli M, Jeen Y-T, Falchuk KR, Peppercorn MA, Michetti P. Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomised controlled trial. Gastroenterology 2003 124 : 917 924.
13. Domènech E, Zabana Y, Mañosa M, Garcia-Planella E, Cabré E, Gassull MA. Infliximab reintroduction is not associated to a higher rate of immune-related adverse effects in patients with inflammatory bowel disease initially treated with a three-infusion induction regimen. J Clin Gastroenterol 2009 [Epub ahead of print].
14. Fidder HH, Schnitzler F, Ferrante M, et al. Long-Term safety of infliximab for the treatment of inflammatory bowel disease: a single centre cohort study. Gut 2009 58 : 501 508.
15. Wagner C, Ford J, Marsters P, Travers S, Bao W, Van Deventer SJ. Effect of antibodies to infliximab on infusion reaction and clinical response in patients with fistulizing Crohn's disease receiving maintenance treatment with infliximab. Gastroenterology 2003 124 (Suppl 1 A380.
16. D'Haens G, Baert F, van Assche G, et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet 2008 371 : 660 667.
17. Schnitzler F, Fidder H, Ferrante M, et al. Long-term outcome of treatment with infliximab in 614 Crohn's disease patients: results from a single centre cohort. Gut 2009 58 : 492 500.
18. Colombel JF, Loftus E, Tremaine W, et al. The safety profile of Infliximab in patients with Crohn's disease: the Mayo Clinic experience in 500 patients. Gastroenterology 2004 126 : 19 31.
19. Ljung T, Karlen P, Schmidt D, et al. Infliximab in inflammatory bowel disease: clinical outcome in a population based cohort from Stockholm County. Gut 2004 53 : 849 853.
20. Lees C, Ali A, Thompson A, et al. The safety profile of anti-tumour necrosis factor therapy in inflammatory bowel disease in clinical practice: analysis of 620 patient-years follow-up. Aliment Pharmacol Ther 2009 29 : 286 297.
21. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001 345 : 1098 1104.
22. Viget N, Vernier-Massouille G, Salmon-Ceron D, Yazdanpanah Y, Colombel JF. Opportunistic infections in patients with inflammatory bowel disease: prevention and diagnosis. Gut 2008 57 : 549 558.
23. Toruner M, Loftus E, Harmsen WS, et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology 2008 134 : 929 936.
24. Bressler B, Korzenik J, Canning C, Solomon D, Schneeweiss S. Infliximab use in patients with inflammatory bowel disease and the risk of serious bacterial infections. Gastroenterology 2008 134 (Suppl 1 A 144 (abstract).
25. Rahier J, Ben-Horin S, Chowers Y, et al., on behalf of the European Crohn's and Colitis Organisation (ECCO) European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. JCC 2009 3 : 47 91.
26. Seksik P, Cosnes J, Sokol H, Nion-Larmurier I, Gendre JP, Beaugeries L. Incidence of benign upper respiratory tract infections, HSV and HPV cutaneous infections in inflammatory bowel disease patients treated with azathioprine. Aliment Pharmacol Ther 2009 15 : 1106 1113.
27. Lavagna A, Bergallo M, Daperno M, et al. Infliximab and the risk of latent viruses reactivation in active Crohn's disease. Inflamm Bowel Dis 2007 13 : 869 902.
28. Duburque C, Lelong J, Iacob R, et al. Successful induction of tolerance to infliximab in patients with Crohn's disease and prior severe infusion reactions. Aliment Pharmacol Ther 2006 24 : 851 858.
29. Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in 23Crohn's disease. N Engl J Med 2003 348 : 601 608.
30. Vermeire S, Noman M, van Assche G, et al. Autoimmunity associated with anti-tumor necrosis factor alpha treatment in Crohn's disease: a prospective cohort study. Gastroenterology 2003 125 : 32 9.
31. De Rycke L, Kruithof E, van Damme N, et al. Antinuclear antibodies following infliximab treatment in patients with rheumatoid arthritis or spondylarthropathy. Arthritis Rheum 2003 48 : 1015 1023.
32. Kapetanovic M, Larsson L, Truedsson L, Sturfelt G, Saxne T, Geborek P. Predictors of infusion reactions during infliximab treatment in patients with arthritis. Arthritis Res Ther 2006 8 : R131 (doi :).
33. Srivasta MD, Alexander F, Tuthill RJ. Immunology of cutaneous vasculitis associated with both etanercept and infliximab. Scabd J Immunol 2005 61 : 329 336.
34. Biancone L, Orlando A, Kohn A, et al. Infliximab and newly diagnosed neoplasia in Crohn's disease: a multicentre matched pair study. Gut 2006 55 : 228 233.
35. Rutgeerts P, van Assche G, Vermeire S. Review article: infliximab for inflammatory bowel disease - seven years on. Aliment Pharmacol Ther 2006 23 : 451 463.